With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
FiercePharma3d
Roche gains label expansion for eye implant Susvimo to treat diabetic macular edema
Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...
The American Journal of Managed Care3d
FDA Approves Ranibizumab Implant in Treatment of DME
The ranibizumab injection could be administered in a convenient schedule twice per year for the treatment of diabetic macular ...
pharmaphorum2d
FDA expands label for Roche's eye disease implant Susvimo
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Daily2d
FDA approves ranibizumab for treating diabetic macular edema
The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...
Business Wire2d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Hosted on MSN1mon
Macular Degeneration Breakthroughs
Study of Lucentis (Ranibizumab ... in a response comparable with monthly intravitreal (inside the back of the eye) injections of anti-VEGF (ranibizumab) treatments. "The PDS was found to be ...
Managed Healthcare Executive3d
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...